GSK (GSK.L) expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter expectations earlier this week, in a boost to its efforts to fuel growth despite product development and tariff challenges.
The British drugmaker is hoping to reach annual sales of over 40 billion pounds ($53.44 billion) by 2031, even as it faces potential pharmaceutical tariffs and drug pricing pressure in the
